Genetic variation of the interleukin-1 family and nongenetic factors determining the interleukin-1 receptor antagonist phenotypes

Metabolism: Clinical and Experimental

Volumn 59, Issue 10, 2010, Pages 1520-1527

  Luotola, Kari ^a   Pietilä, Arto ^b   Alanne, Mervi ^c   Lanki, Timo ^b   Loo, Britt Marie ^b   Jula, Antti ^b   Perola, Markus ^b,d   Peters, Annette ^e   Zeller, Tanja ^f   Blankenberg, Stefan ^f   Salomaa, Veikko ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c WIHURI RESEARCH INSTITUTE   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

^e INSTITUTE OF EPIDEMIOLOGY   (Germany)

^f JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; IL1RN PROTEIN, HUMAN; INTERLEUKIN 1;

ADULT; AGED; ALLELE; ARTICLE; BODY MASS; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEALTH SURVEY; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVOR; CLASSIFICATION; CLINICAL TRIAL; GENE FREQUENCY; GENETICS; LONGITUDINAL STUDY; META ANALYSIS (TOPIC); MIDDLE AGED; MULTICENTER STUDY; MULTIGENE FAMILY; MYOCARDIAL INFARCTION; PHYSIOLOGY; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; FEMALE; GENE FREQUENCY; GENETIC VARIATION; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; LONGITUDINAL STUDIES; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; MULTIGENE FAMILY; MYOCARDIAL INFARCTION; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; SURVIVORS;

EID: 77956978000     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2010.01.017     Document Type: Article

References (27)

1. Libby P. Inflammation in atherosclerosis Nature 420 2002 868 874
2. Juge-Aubry C.E., Somm E., Giusti V., Pernin A., Chicheportiche R., and Verdumo C. Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation Diabetes 52 2003 1104 1110
3. Meier C.A., Bobbioni E., Gabay C., Assimacopoulos-Jeannet F., Golay A., and Dayer J.M. IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin? J Clin Endocrinol Metab 87 2002 1184 1188
4. Herder C., Brunner E.J., Rathmann W., Strassburger K., Tabak A.G., and Schloot N.C. Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: the Whitehall II study Diabetes Care 32 2009 421 423
5. Larsen C.M., Faulenbach M., Vaag A., Volund A., Ehses J.A., and Seifert B. Interleukin-1-receptor antagonist in type 2 diabetes mellitus N Engl J Med 356 2007 1517 1526
6. Rafiq S., Stevens K., Hurst A.J., Murray A., Henley W., and Weedon M.N. Common genetic variation in the gene encoding interleukin-1-receptor antagonist (IL-1RA) is associated with altered circulating IL-1RA levels Genes Immun 8 2007 344 351
7. Melzer D., Perry J.R., Hernandez D., Corsi A.M., Stevens K., and Rafferty I. A genome-wide association study identifies protein quantitative trait loci (pQTLs) PLoS Genet 4 2008 e1000072
8. Reiner A.P., Wurfel M.M., Lange L.A., Carlson C.S., Nord A.S., and Carty C.L. Polymorphisms of the IL1-receptor antagonist gene (IL1RN) are associated with multiple markers of systemic inflammation Arterioscler Thromb Vasc Biol 28 2008 1407 1412
9. Aromaa A, Koskinen S. 2004 Health and functional capacity in Finland. Baseline results of the Health 2000 health examination survey. Publications of the National Public Health Institute B12/2004. Helsinki.
10. Peters A., Schneider A., Greven S., Bellander T., Forastiere F., and Ibald-Mulli A. Air pollution and inflammatory response in myocardial infarction survivors: gene-environment interactions in a high-risk group Inhal Toxicol 19 Suppl 1 2007 161 175
11. Vartiainen E., Jousilahti P., Alfthan G., Sundvall J., Pietinen P., and Puska P. Cardiovascular risk factor changes in Finland, 1972-1997 Int J Epidemiol 29 2000 49 56
12. Barrett J.C., Fry B., Maller J., and Daly M.J. Haploview: analysis and visualization of LD and haplotype maps Bioinformatics 21 2005 263 265
13. Gabriel S.B., Schaffner S.F., Nguyen H., Moore J.M., Roy J., and Blumenstiel B. The structure of haplotype blocks in the human genome Science 296 2002 2225 2229
14. Stephens M., and Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data Am J Hum Genet 73 2003 1162 1169
15. Marculescu R., Endler G., Schillinger M., Iordanova N., Exner M., and Hayden E. Interleukin-1 receptor antagonist genotype is associated with coronary atherosclerosis in patients with type 2 diabetes Diabetes 51 2002 3582 3585
16. Luotola K., Paakkonen R., Alanne M., Lanki T., Moilanen L., and Surakka I. Association of variation in the interleukin-1 gene family with diabetes and glucose homeostasis J Clin Endocrinol Metab 94 2009 4575 4583
17. Jager J., Gremeaux T., Cormont M., Le Marchand-Brustel Y., and Tanti J.F. Interleukin-1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression Endocrinology 148 2007 241 251
18. Maedler K., Sergeev P., Ehses J.A., Mathe Z., Bosco D., and Berney T. Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets Proc Natl Acad Sci U S A 101 2004 8138 8143
19. Elbein S.C., Das S.K., Hallman D.M., Hanis C.L., and Hasstedt S.J. Genome-wide linkage and admixture mapping of type 2 diabetes in African American families from the American Diabetes Association GENNID (Genetics of NIDDM) study cohort Diabetes 58 2009 268 274
20. Dupuis J., Langenberg C., Prokopenko I., Saxena R., Soranzo N., and Jackson A.U. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk Nat Genet 42 2010 105 116
21. van Minkelen R., Wettinger S.B., de Visser M.C., Vos H.L., Reitsma P.H., and Rosendaal F.R. Haplotypes of the interleukin-1 receptor antagonist gene, interleukin-1 receptor antagonist mRNA levels and the risk of myocardial infarction Atherosclerosis 203 2009 201 205
22. Enquobahrie D.A., Rice K., Williams O.D., Williams M.A., Gross M.D., and Lewis C.E. IL1B genetic variation and plasma C-reactive protein level among young adults: the CARDIA study Atherosclerosis 202 2009 513 520
23. Iacoviello L., Di Castelnuovo A., Gattone M., Pezzini A., Assanelli D., and Lorenzet R. Polymorphisms of the interleukin-1beta gene affect the risk of myocardial infarction and ischemic stroke at young age and the response of mononuclear cells to stimulation in vitro Arterioscler Thromb Vasc Biol 25 2005 222 227
24. Zee R.Y., Hennessey H., Michaud S.E., and Ridker P.M. Genetic variants within the interleukin-1 gene cluster, and risk of incident myocardial infarction, and ischemic stroke: a nested case-control approach Atherosclerosis 201 2008 124 129
25. Chamberlain J., Francis S., Brookes Z., Shaw G., Graham D., and Alp N.J. Interleukin-1 regulates multiple atherogenic mechanisms in response to fat feeding PLoS ONE 4 2009 e5073
26. Isoda K., Shiigai M., Ishigami N., Matsuki T., Horai R., and Nishikawa K. Deficiency of interleukin-1 receptor antagonist promotes neointimal formation after injury Circulation 108 2003 516 518
27. Devlin C.M., Kuriakose G., Hirsch E., and Tabas I. Genetic alterations of IL-1 receptor antagonist in mice affect plasma cholesterol level and foam cell lesion size Proc Natl Acad Sci U S A 99 2002 6280 6285